Who Paid My Doc
Kimberley Sampson
Obesity Medicine Bennington, VT Medical Doctor
NPI 1013271451 CMS profile 1217798
140 Hospital Dr, Bennington, VT 05201
General payments
$19,582
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Kimberley Sampson of Bennington, VT is reported in the CMS Open Payments database as having received $19,582 across 13 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $19,559 | 12 | |
| 2022 | General | $23 | 1 |
Beside peers
- Kimberley Sampson
- Vermont median
- Middle half of Vermont
- National median
In program year 2025, general payments to Kimberley Sampson were reported at $19,559. Among 430 Vermont profiles paid that year, the median was $119 and the middle half received between $39 and $763.
Show as a table
| Year | Kimberley Sampson | Vermont median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $123 | $34–$988 | $163 |
| 2020 | $0 | $90 | $29–$627 | $114 |
| 2021 | $0 | $82 | $21–$371 | $132 |
| 2022 | $23 | $97 | $27–$459 | $149 |
| 2023 | $0 | $119 | $25–$623 | $160 |
| 2024 | $0 | $113 | $27–$738 | $164 |
| 2025 | $19,559 | $119 | $39–$763 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
256
Drug cost
$73,786
Branded share of claims
48.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Wegovy Semaglutide | Brand | 14 | $17,767 | |
| Trulicity Dulaglutide | Brand | 18 | $16,383 | |
| Mounjaro Tirzepatide | Brand | 14 | $14,687 | |
| Ozempic Semaglutide | Brand | 12 | $10,545 | |
| Estradiol | Generic | 54 | $5,757 | |
| Premarin Estrogens, Conjugated | Brand | 12 | $5,739 | |
| Bupropion Xl Bupropion Hcl | Brand | 31 | $862 | |
| Valacyclovir Valacyclovir Hcl | Brand | 13 | $688 | |
| Clobetasol Propionate | Generic | 17 | $512 | |
| Naltrexone Hcl | Generic | 14 | $503 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 26 billing codesPaid by Medicare
$21,458
Medicare patients
146
Services billed
361
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 41% | |
| Arthritis | 36% | |
| Depression | 24% | |
| Osteoporosis | 22% | |
| Diabetes | 16% | |
| Cancer | 14% | |
| COPD | 8% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Obesity Medicine in Vermont
Practitioners in the same specialty and state, ranked by reported value.
All Obesity Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Vermont
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.